Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 13,625 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Bacterial Infections, Diabetic Foot, Osteomyelitis
Interventions: Tigecycline, Ertapenem; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,061 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 26
States / cities: Los Angeles, California • Northridge, California • San Francisco, California + 20 more

Conditions: Cancer
Interventions: Experimental: Mentored Gardening Intervention; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 60 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Cervical Carcinoma, Metastatic Ovarian Carcinoma, Malignant Uterine Neoplasm, Vulvar Cancer, Invasive Breast Cancer, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Vulvar Carcinoma, Stage IV Cervical Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vulva Squamous Cell Carcinoma
Interventions: Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Colorectal Neoplasms, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: SGN-2FF, pembrolizumab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 11
States / cities: Birmingham, Alabama • Duarte, California • Aurora, Colorado + 8 more

Conditions: Breast Cancer, Neurotoxicity
Interventions: Ginkgo Biloba, Placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2015
U.S. locations: 175
States / cities: Scottsdale, Arizona • Lompoc, California • Santa Barbara, California + 111 more

Conditions: Healthy
Interventions: PD-0332991; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer, Lung Cancer, Triple Negative Breast Cancer, Breast Neoplasms, Neuroendocrine Tumors, Neuroendocrine Carcinoma, RB1 Gene Mutation
Interventions: CID-078 Monotherapy; Drug
Lead sponsor: Circle Pharma; Industry
Eligibility: 12 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 7 more

Conditions: Locally Recurrent/Metastatic Triple Negative Breast Cancer
Interventions: external beam radiation therapy, cisplatin, Biopsy of Target Tumor; Radiation · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Pressure Ulcers (Hospital-acquired Pressure Injuries)
Interventions: ALLEVYN◊ COMPLETE CARE Sacrum; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Grand Junction, Colorado • Atlanta, Georgia • Indianapolis, Indiana

Conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Lymphoma Cancer, Gynecological Cancers
Interventions: group intervention and questionnaires, individual phone intervention and questionnaires, expressive writing (arm will not be include in the randomization); Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 70 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Imaging on experimental tomo device; Radiation
Lead sponsor: Philips Digital Mammography Sweden AB; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Carcinoma
Interventions: Counseling, Written materials; Behavioral
Lead sponsor: American Scitech International; Other
Eligibility: 25 Years to 85 Years · Female only
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Englishtown, New Jersey

Conditions: Melanoma, Head and Neck Cancer, Sarcoma, Non-Melanoma Skin Cancers
Interventions: Hiltonol; Biological
Lead sponsor: Oncovir, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: Chevy Chase, Maryland • Easton, Maryland • Columbia, Missouri + 1 more

Conditions: Staphylococcal Skin Infection
Interventions: TD-1792, Vancomycin; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: National City, California

Conditions: Neoplasm Metastasis, Melanoma
Interventions: Diphenylcyclopropenone (DPCP); Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer
Interventions: Switch, Guideline Directed Intervention (GDI); Drug · Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Hidradenitis Suppurativa
Interventions: Alexandrite Laser; Device
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Dearborn, Michigan

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 35 Years to 80 Years · Female only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hand-foot Skin Reaction, Rash
Interventions: urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, bland emollient cream (Udderly smooth® Udder Cream); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Pain, Lymphedema Arm
Interventions: The-Optimal-Lymph-Flow; Behavioral
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years to 89 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Pityriasis Rubra Pilaris
Interventions: Bimekizumab; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: HER2/Neu Positive, HLA-A2 Positive Cells Present, Stage IV Breast Cancer, Stage IV Ovarian Cancer
Interventions: HER-2/neu Peptide Vaccine, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 19 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: Edotecarin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 7
States / cities: Manhasset, New York • New York, New York • Cleveland, Ohio + 3 more

Conditions: Dercum's Disease
Interventions: 10 mg CBL-514 per injection, 15 mg CBL-514 per injection; Drug
Lead sponsor: Caliway Biopharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors

Paclitaxel Therapeutic Drug Monitoring in Cancer Patients

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer

Relative Bioavailability Study

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Sacrum Pressure Injury Prevention Study Using ALLEVYN◊ Complete Care in Adults at Risk of Developing Hospital-acquired Pressure Injuries in Critical Care Units

A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer

Comparison of the Philips MicroDose Tomosynthesis System to 2D Digital Mammography

Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)

Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients

Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser

Breast Cancer, Breast Disease, and Pesticides

Sorafenib-induced Hand- Foot Skin Reaction Treatment

Advancing Patient Care for Lymphatic Pain and Lymphedema

Bimzelx (Bimekizumab) For The Treatment Of Adult Onset Pityriasis Rubra Pilaris (PRP)

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas